Eravacycline is a tetracycline antibiotic used to treat complicated intra-abdominal infections. Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria.
- Mechanism
- Curator reviewed
Eravacycline is a fluorocycline antibacterial of the tetracycline class of antibacterial drugs. Eravacycline disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the incorporation of amino acid residues into elongating peptide chains. In general, eravacycline is bacteriostatic against gram-positive bacteria (e.g., Staphylococcus aureus and Enterococcus faecalis); however, in vitro bactericidal activity has been shown against certain strains of Escherichia coli and Klebsiella pneumoniae.
- Primary indication
- Eravacycline is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.Curator reviewed · 1 structured indication
- Formula / weight
- C27H31FN4O8 · 558.563 g/mol (avg)
- First approval
- United States, 2018 · European Union, 2020
- Code names
- TP-434
- Brand names
Resolves to
HLFSMUUOKPBTSM-ISIOAQNYSA-NSMILES[H][C@@]12CC3=C(F)C=C(NC(=O)CN4CCCC4)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2What you can answer from here — as of September 23, 2026
Which drugs share a target with Eravacycline, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account